Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (2)
  • Open Access

    REVIEW

    Comprehensive review of male breast cancer: Understanding a rare condition

    ABDUR JAMIL1, RIMSHA SIDDIQUE2, FARYAL ALTAF3, DANIYAL WARRAICH4, FAIZAN AHMED5, ZAHEER QURESHI6,*

    Oncology Research, Vol.33, No.6, pp. 1289-1300, 2025, DOI:10.32604/or.2025.058790 - 29 May 2025

    Abstract Background: Male breast cancer (MBC) is a rare but significant health concern, accounting for less than 1% of all breast cancer cases. Despite its low incidence, it presents unique clinical, genetic, and psychosocial challenges. Genetic predispositions, including BRCA2 mutations and hormonal imbalances, are key factors influencing the development of MBC. However, the rarity of the condition has led to limited research and fewer treatment guidelines specifically for male patients. Methods: A comprehensive literature review was conducted using PubMed, MEDLINE, and Embase databases to identify studies focusing on the epidemiology, risk factors, clinical presentation, diagnosis, treatment,… More >

  • Open Access

    REVIEW

    Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

    DHANYA K. NAMBIAR1, DEEPALI MISHRA2, RANA P. SINGH2,3,*

    Oncology Research, Vol.31, No.4, pp. 405-421, 2023, DOI:10.32604/or.2023.028310 - 25 June 2023

    Abstract Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 (PARP-1) causing resistance to radiation therapy. Thus, PARP-1 represents an important target in multiple cancer types, including prostate cancer. PARP is a nuclear enzyme essential for single-strand DNA breaks repair. Inhibiting PARP-1 is lethal in a wide range of cancer cells that lack the homologous recombination repair (HR) pathway. This article provides a concise and simplified overview of the development of PARP inhibitors in the laboratory and their clinical More > Graphic Abstract

    Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials

Displaying 1-10 on page 1 of 2. Per Page